Search
Hydroxyethyl ethylcellulose
go.drugbank.com/drugs/DB14139ApprovedHydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.
Categories: Compounds used in a research, industrial, or household settingNicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnNicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. … Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].
Phloxine B
go.drugbank.com/drugs/DB13911ApprovedWithdrawnPhloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing
Categories: Compounds used in a research, industrial, or household settingSilver sulfadiazine
go.drugbank.com/drugs/DB05245ApprovedInvestigationalVet approvedSilver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigationalFludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.
Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalFDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … FDA on July 13, 2020.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Neratinib is currently under investigation for use in many other forms of cancer.